CD8-specific antibody constructs and compositions thereof
AssigneeSana Biotechnology, Inc.
InventorsPatricia Ann Cruite, Shirisha Amatya, Hugh Harding, Lauren Pepper MacKenzie
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.
Claims30
A viral vector targeting CD8+ T cells, comprising:
- i) an antibody fragment that binds CD8;
- ii) a henipavirus envelope glycoprotein G (G protein) or a biologically active portion thereof;
- iii) a henipavirus F protein molecule or biologically active portion thereof;
- and
- iv) one or more nucleic acid sequences encoding a chimeric antigen receptor (CAR),
- wherein the antibody fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise:
- a) SEQ ID NOs:
- 1, 70, 148, 240, 294, 333, respectively;
- b) SEQ ID NOs:
- 5, 74, 150, 242, 295, 336, respectively;
- c) SEQ ID NOs:
- 40, 109, 189, 240, 294, 370, respectively;
- or
- d) SEQ ID NOs:
- 43, 77, 196, 270, 320, 375, respectively;
- and
- wherein the antibody fragment is attached to the C-terminus of the G protein or the biologically active portion thereof.
A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a composition comprising a lipid particle comprising an antibody fragment that binds CD8, a henipavirus envelope glycoprotein G (G protein) or a biologically active portion thereof, a henipavirus F protein molecule or biologically active portion thereof, and a chimeric antigen receptor (CAR),
- wherein the antibody fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise:
- a) SEQ ID NOs:
- 1, 70, 148, 240, 294, 333, respectively;
- b) SEQ ID NOs:
- 5, 74, 150, 242, 295, 336, respectively;
- c) SEQ ID NOs:
- 40, 109, 189, 240, 294, 370, respectively;
- or
- d) SEQ ID NOs:
- 43, 77, 196, 270, 320, 375, respectively.
Dependencies are inferred from the claim text.